MDS/AML separated into those with TP53 mutations (19/137; 14%), with MR gene mutations (99/137; 72%), with MR cytogenetic abnormalities (6/137; 4%) and MDS/AML, NOS (13/137; 10%). Here, TP53 is linked to acute myeloid leukemia.